ERBB2 and breast carcinoma: The use of poly (ADP-ribose) polymerase (PARP) inhibitors as monotherapy has shown significant improvements in the PFS (progression-free survival) compared to chemotherapy in metastatic HER2-mutated germline BRCA breast cancer [31,32].